---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Humanistic burden and health-related quality of life. Topics: Quality of life, functioning, and work productivity in TRD versus non-TRD MDD: Sequenced Treatment Alternatives to Relieve Depression trial secondary analysis; EQ-5D-5L utility and work productivity in TRD versus non-TRD MDD: United Kingdom non-interventional study; EQ-5D-5L, SF-12v2, and work and activity impairment versus non-TRD depression and the general population: five European countries; EQ-5D-5L, employment, and work productivity at treatment initiation: European real-world TRD cohort; 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### Quality of life, functioning, and work productivity in TRD versus non-TRD MDD: Sequenced Treatment Alternatives to Relieve Depression trial secondary analysis

> “A total of 2467 (TRD: 377; non-TRD: 2090) patients were studied.”
> “During follow-up, TRD patients had lower health-related quality of life (HRQOL) scores on mental (30 vs 45.7) and physical components (47.7 vs 48.9) of the SF12, and lower Q-LES-Q scores (43.6 vs 63.7), greater functional and work impairments and productivity loss vs non-TRD patients (all p < 0.05).”

Source: [DiBernardo et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6206859/)

| Endpoint | TRD | Non-TRD | P value |
| --- | --- | --- | --- |
| SF-12 mental component score | “30.0” | “45.7” | “<.0001” |
| SF-12 physical component score | “47.7” | “48.9” | “0.0126” |
| Q-LES-Q general activities index | “43.6” | “63.7” | “<.0001” |
| Work and Social Adjustment Scale score | “23.4” | “11.3” | “<.0001” |
| WPAI activity impairment, % | “54.5” | “30.5” | “<.0001” |
| WPAI percent hours missed | “19.6” | “9.5” | “<.0001” |
| WPAI overall work impairment, % | “52.9” | “24.9” | “<.0001” |

Source: [DiBernardo et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6206859/)

<a id="topic-2.2.1.8.1-2"></a>

### EQ-5D-5L utility and work productivity in TRD versus non-TRD MDD: United Kingdom non-interventional study

> “148 patients with clinician-verified symptomatic (non-treatment-resistant) MDD (Patients-MDD; n = 61) or TRD (Patients-TRD; n = 87) were recruited from ten clinical sites.”
> “However, HRQoL was significantly poorer for Patients-TRD compared with Patients-MDD, both in the overall cohort (median EQ-5D-5 L utility 0.606/0.721, respectively [p = 0.021]; WHOQOL-BREF overall score 55.2/58.8 [p = 0.024]) and in patients with a PHQ-9 score ≥15 (median EQ-5D-5 L utility 0.415/0.705, respectively [p<0.001]).”
> “Although a numerically lower proportion of Patients-TRD were employed (45% vs 57% of Patients-MDD; p = 0.204), employed Patients-MDD reported significantly higher absenteeism and work productivity loss.”

Source: [Rathod et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34965398/)

<a id="topic-2.2.1.8.1-3"></a>

### EQ-5D-5L, SF-12v2, and work and activity impairment versus non-TRD depression and the general population: five European countries

> “A total 52,060 survey respondents were examined, of which 2686 and 622 were considered to have non-treatment resistant and treatment-resistant depression, respectively.”
> “Relative to the general population, nTRD and TRD respondents reported significant decrements in health-related quality of life, including lower adjusted mental (− 12.1 vs. -18.1) and physical (− 2.5 vs. -5.4) component scores of the SF-12v2 and increased adjusted relative risk for work (2.2 vs. 2.7) and activity (1.9 vs. 2.5) impairment (all p < 0.001).”
> “After adjusting for demographics and health characteristics, TRD and nTRD groups had poorer health status as assessed by the EQ-5D-5 L (− 0.329 and − 0.173, respectively, both p < 0.001) and EQ-VAS (− 27.440 and − 16.724, respectively, both p < 0.001) compared to the general population.”

Source: [Jaffe et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6686569/)

<a id="topic-2.2.1.8.1-4"></a>

### EQ-5D-5L, employment, and work productivity at treatment initiation: European real-world TRD cohort

> “Overall, 411 eligible patients were enrolled across seven European countries.”
> “Long-term sick leave was reported by 19.0% of patients; 30.2% were unemployed.”
> “At baseline, mean (SD) HRQoL scores for EuroQoL 5-dimension 5-level (UK tariff) and EQ-Visual Analog Scale were 0.41 (0.25) and 41.1 (18.7), respectively.”
> “The Work Productivity and Activity Impairment questionnaire demonstrated mean (SD) absenteeism of 57.0% (44.9%) and presenteeism of 54.7% (29.5%); mean (SD) overall work impairment was 60.5% (29.9%).”

Source: [Heerlein et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33545659/)

<a id="topic-2.2.1.8.1-5"></a>

### Proportion reporting problems on each EQ-5D-5L dimension at baseline: esketamine phase 3 trial population

> “The full analysis set included 223 patients (ESK + AD: 114; AD + PBO: 109; mean [SD] age: 45.7 [11.89]).”

Source: [Jamieson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10169482/)

| EQ-5D-5L dimension | Esketamine plus antidepressant group at baseline, % | Antidepressant plus placebo group at baseline, % |
| --- | --- | --- |
| Mobility | “28.1” | “34.9” |
| Self-care | “53.5” | “53.2” |
| Usual activities | “94.8” | “92.7” |
| Pain/Discomfort | “68.5” | “74.3” |
| Anxiety/Depression | “98.3” | “99.9” |

Source: [Jamieson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10169482/)

<a id="topic-2.2.1.8.1-6"></a>

### Quality-of-life decrement versus remission or response: systematic review of United States data, 1996 to 2013

> “Sixty-two articles were included (N=59,462 patients).”
> “Quality-of-life scores (scale of 0-1, with 0 indicating death and 1 indicating perfect health) for patients with treatment-resistant depression were .41±.8 and .26±.8 points lower, respectively, than for patients who experienced remission or response.”

Source: [Mrazek et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24789696/)

<a id="topic-2.2.1.8.1-7"></a>

### Quality of life across increasing levels of non-response: systematic review

> “Likewise, the 19 studies studying HRQoL burden found that increasing levels of TRD/non-response correlated with reduced patient HRQoL and health status.”
> “A consistent trend was observed such that medical costs increased and patient HRQoL and health status decreased by increasing level of TRD/non-response within an MDD episode.”

Source: [Johnston et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30195173/)

<a id="topic-2.2.1.8.1-8"></a>

### Health state utilities by depression severity used in a United States cost-effectiveness model of esketamine

> “Patient EQ-5D health index scores were measured at baseline and stratified according to baseline PHQ-9 levels of mild (< 10), moderate (11 to 15), moderately-severe (16 to 20), and severe depression (> 20).”
> “Characteristics of patients in this study were similar to those in the TRANSFORM trials, with an average number of 3.6 treatment failures and PHQ-9 score of 18.3.”

Source: [ICER final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf)

| Health state | Base-case utility |
| --- | --- |
| No depression, gender adjusted | “0.86” |
| Mild to moderate depression | “0.68” |
| Severe depression | “0.50” |

Source: [ICER final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
